Chimeric Therapeutics LimitedASX: CHM

Completion of retail component of Entitlement Offer

· Issued by Chimeric Therapeutics Limited

Filed with ASX · · 2 pages · English

On 21 February 2022, Chimeric Therapeutics Limited (ASX:CHM) (Chimeric orCompany) announced the details of an accelerated non-renounceable entitlement offer (Entitlement Offer) to raise approximately $18 million (before costs of the offer). Chimeric announced the successful completion of the Institutional component of the Entitlement Offer on 23 February 2022, which raised approximately $7.4 milli

Chimeric Therapeutics Limited on 6ix

Story so far

Earlier from Chimeric Therapeutics

Later from Chimeric Therapeutics

All Chimeric Therapeutics news releases